drugset / Trial / NCT07694557
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
RandomizedParallel-groupDouble-blindPrevention
Summary
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
Timeline
- Start
- 2026-07-15
- Primary completion
- 2028-07-01
- Completion
- 2028-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | YKYY025 | Messenger RNA (mRNA) | — | Intramuscular |